T2DM Archives - Medical Conferences

Finerenone lowers CV events in diabetic CKD patients

Presented By

Prof. Gerasimos Filippatos, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, FIDELIO-DKD

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:33

Dapagliflozin reduces renal risk independent of CV disease status

Presented By

Prof. John McMurray, University of Glasgow, Scotland

Trial

DAPA-CKD

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:18

“Strongly consider an SGLT2-inhibitor in most T2DM patients”

Presented By

Prof. Deepak Bhatt, Brigham and Women’s Hospital, USA

Trial

Phase 3, SOLOIST-WHF; SCORED

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:14

2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines

Presented By

Prof. Antonio Pelliccia, Institute of Sports Medicine and Science, Italy

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:53

SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients

Presented By

Dr Milton Packer, Baylor University Medical Center, USA

Trial

Phase 3, EMPEROR-Reduced trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:40

Antisense ANGPTL3 lowers triglycerides

Presented By

Prof. Daniel Gaudet, University of Montréal, Canada

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:50

SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations

Presented By

Prof. Francesco Cosentino, Karolinska University Hospital, Sweden

Trial

VERTIS CV

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:39